Respiratory syncytial virus (RSV) vaccines-Two steps back for one leap forward

Journal of Clinical Virology

Volumn 41, Issue 1, 2008, Pages 38-44

  Power, Ultan F ^a  

^a Centre for Cancer Research and Cell Biology   (United Kingdom)

Author keywords

Immune response evasion; Respiratory syncytial virus; RSV ex vivo models of infection; Vaccine

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; INTERFERON; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ADAPTIVE IMMUNITY; ARTICLE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS CELL INTERACTION; VIRUS CLASSIFICATION; VIRUS INFECTION; VIRUS MORPHOLOGY;

HUMANS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 37349028337     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2007.10.024     Document Type: Article

References (78)

1. Alwan W.H., Kozlowska W.J., and Openshaw P.J. Distinct types of lung disease caused by functional subsets of antiviral T cells. J Exp Med 179 1 (1994) 81-89
2. Alwan W.H., and Openshaw P.J. Distinct patterns of T- and B-cell immunity to respiratory syncytial virus induced by individual viral proteins. Vaccine 11 4 (1993) 431-437
3. Arnold R., Konig B., Werchau H., and Konig W. Respiratory syncytial virus deficient in soluble G protein induced an increased proinflammatory response in human lung epithelial cells. Virology 330 2 (2004) 384-397
4. Beem M. Repeated infections with respiratory syncytial virus. J Immunol 98 6 (1967) 1115-1122
5. Bossert B., and Conzelmann K.K. Respiratory syncytial virus (RSV) nonstructural (NS) proteins as host range determinants: a chimeric bovine RSV with NS genes from human RSV is attenuated in interferon-competent bovine cells. J Virol 76 9 (2002) 4287-4293
6. Bouveret Le Cam N., Nguyen T.N., Corvaia, N, Power U.F., Libon C., Tabary X. et al. Safety and immunogenicity of BBG2Na a RSV subunit vaccine based on G derived recombinant protein in the elderly: a phase II study. Sep. 17, Washington, DC; 2000.
7. Bukreyev A., Whitehead S.S., Murphy B.R., and Collins P.L. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J Virol 71 12 (1997) 8973-8982
8. Byrd L.G., and Prince G.A. Animal models of respiratory syncytial virus infection. Clin Infect Dis 25 6 (1997) 1363-1368
9. Chi B., Dickensheets H.L., Spann K.M., Alston M.A., Luongo C., Dumoutier L., et al. Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J Virol 80 10 (2006) 5032-5040
10. Collins P.L., Purcell R.H., London W.T., Lawrence L.A., Chanock R.M., and Murphy B.R. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. Vaccine 8 2 (1990) 164-168
11. Collins P.L., Chanock R.M., and Murphy B.R. Respiratory syncytial virus. In: Knipe D.M., Howley P.M., et al. (Eds). Field's Virology (2001), Lippincott Williams & Wilkins, Philadelphia 1443-1485
12. Crowe Jr. J.E. Host responses to respiratory virus infection and immunization. Curr Top Microbiol Immunol 236 (1999) 191-214
13. Crowe Jr. J.E., Collins P.L., London W.T., Chanock R.M., and Murphy B.R. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 11 14 (1993) 1395-1404
14. Decker T., Muller M., and Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol 5 9 (2005) 675-687
15. Doherty G.M., Christie S.N., Skibinski G., Puddicombe S.M., Warke T.J., de Courcey F., et al. Non-bronchoscopic sampling and culture of bronchial epithelial cells in children. Clin Exp Allergy 33 9 (2003) 1221-1225
16. Edwards K.M., Dupont W.D., Westrich M.K., Plummer Jr. W.D., Palmer P.S., and Wright P.F. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 169 1 (1994) 68-76
17. Elango N., Prince G.A., Murphy B.R., Venkatesan S., Chanock R.M., and Moss B. Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein. Proc Natl Acad Sci USA 83 6 (1986) 1906-1910
18. Elliott J., Lynch O.T., Suessmuth Y., Qian P., Boyd C.R., Burrows J.F., et al. Respiratory syncytial virus NS1 protein degrades STAT2 by using the Elongin-Cullin E3 ligase. J Virol 81 7 (2007) 3428-3436
19. Fuentes S., Tran K.C., Luthra P., Teng M.N., and He B. Function of the respiratory syncytial virus small hydrophobic protein. J Virol 81 15 (2007) 8361-8366
20. Glezen W.P., Taber L.H., Frank A.L., and Kasel J.A. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 140 6 (1986) 543-546
21. Gonzalez-Reyes L., Ruiz-Arguello M.B., Garcia-Barreno B., Calder L., Lopez J.A., Albar J.P., et al. Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc Natl Acad Sci USA 98 17 (2001) 9859-9864
22. Graham B.S., Perkins M.D., Wright P.F., and Karzon D.T. Primary respiratory syncytial virus infection in mice. J Med Virol 26 2 (1988) 153-162
23. Hall C.B. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 344 25 (2001) 1917-1928
24. Hall C.B., Walsh E.E., Long C.E., and Schnabel K.C. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 163 4 (1991) 693-698
25. Harcourt J., Alvarez R., Jones L.P., Henderson C., Anderson L.J., and Tripp R.A. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J Immunol 176 3 (2006) 1600-1608
26. Harkensee C., Brodlie M., Embleton N.D., and Mckean M. Passive immunisation of preterm infants with palivizumab against RSV infection. J Infect 52 1 (2006) 2-8
27. Heaney J., Barrett T., and Cosby S.L. Inhibition of in vitro leukocyte proliferation by morbilliviruses. J Virol 76 7 (2002) 3579-3584
28. Heidema J., de Bree G.J., de Graaff P.M., van Maren W.W., Hoogerhout P., Out T.A., et al. Human CD8(+) T cell responses against five newly identified respiratory syncytial virus-derived epitopes. J Gen Virol 85 Pt. 8 (2004) 2365-2374
29. Henderson F.W., Collier A.M., Clyde Jr. W.A., and Denny F.W. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med 300 10 (1979) 530-534
30. Hendricks D.A., Baradaran K., McIntosh K., and Patterson J.L. Appearance of a soluble form of the G protein of respiratory syncytial virus in fluids of infected cells. J Gen Virol 68 Pt. 6 (1987) 1705-1714
31. Horvath C.M., Stark G.R., Kerr I.M., and Darnell Jr. J.E. Interactions between STAT and non-STAT proteins in the interferon-stimulated gene factor 3 transcription complex. Mol Cell Biol 16 12 (1996) 6957-6964
32. Jin H., Cheng X., Traina-Dorge V.L., Park H.J., Zhou H., Soike K., et al. Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Vaccine 21 25-26 (2003) 3647-3652
33. Johnson T.R., Johnson J.E., Roberts S.R., Wertz G.W., Parker R.A., and Graham B.S. Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J Virol 72 4 (1998) 2871-2880
34. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89 4 (1969) 422-434
35. Kochs G., Garcia-Sastre A., and Martinez-Sobrido L. Multiple anti-interferon actions of the influenza A virus NS1 protein. J Virol 81 13 (2007) 7011-7021
36. Langedijk J.P., de Groot B.L., Berendsen H.J., and van Oirschot J.T. Structural homology of the central conserved region of the attachment protein G of respiratory syncytial virus with the fourth subdomain of 55-kDa tumor necrosis factor receptor. Virology 243 2 (1998) 293-302
37. Lo M.S., Brazas R.M., and Holtzman M.J. Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. J Virol 79 14 (2005) 9315-9319
38. Matthews N.C., Power U.F., and Reen D.J. Neonatal human autologous dendritic cells pulsed with recombinant protein antigen prime the generation of non-polarized CD4 T-cell effectors. Int Immunol 19 6 (2007) 703-712
39. Meissner H.C. Selected populations at increased risk from respiratory syncytial virus infection. Pediatr Infect Dis J 22 Suppl. 2 (2003) S40-S44
40. Meissner H.C., and Long S.S. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 112 6 Pt. 1 (2003) 1447-1452
41. Murphy B.R., Graham B.S., Prince G.A., Walsh E.E., Chanock R.M., Karzon D.T., et al. Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J Clin Microbiol 23 6 (1986) 1009-1014
42. Murphy B.R., Sotnikov A., Paradiso P.R., Hildreth S.W., Jenson A.B., Baggs R.B., et al. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine 7 6 (1989) 533-540
43. Olmsted R.A., Elango N., Prince G.A., Murphy B.R., Johnson P.R., Moss B., et al. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci USA 83 19 (1986) 7462-7466
44. Parveen S., Broor S., Kapoor S.K., Fowler K., and Sullender W.M. Genetic diversity among respiratory syncytial viruses that have caused repeated infections in children from rural India. J Med Virol 78 5 (2006) 659-665
45. Piedra P.A. Clinical experience with respiratory syncytial virus vaccines. Pediatr Infect Dis J 22 Suppl. 2 (2003) S94-S99
46. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5 5 (2005) 375-386
47. Platanias L.C., Uddin S., and Colamonici O.R. Tyrosine phosphorylation of the alpha and beta subunits of the type I interferon receptor. Interferon-beta selectively induces tyrosine phosphorylation of an alpha subunit-associated protein. J Biol Chem 269 27 (1994) 17761-17764
48. Plotnicky-Gilquin H., Huss T., Aubry J.P., Haeuw J.F., Beck A., Bonnefoy J.Y., et al. Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment. Virology 258 1 (1999) 128-140
49. Polack F.P., Irusta P.M., Hoffman S.J., Schiatti M.P., Melendi G.A., Delgado M.F., et al. The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Proc Natl Acad Sci USA 102 25 (2005) 8996-9001
50. Power U.F., Nguyen T.N., Rietveld E., de Swart R.L., Groen J., Osterhaus A.D., et al. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J Infect Dis 184 11 (2001) 1456-1460
51. Power U.F., Plotnicky H., Blaecke A., and Nguyen T.N. The immunogenicity, protective efficacy and safety of BBG2Na, a subunit respiratory syncytial virus (RSV) vaccine candidate, against RSV-B. Vaccine 22 2 (2003) 168-176
52. Power U.F., Plotnicky-Gilquin H., Huss T., Robert A., Trudel M., Stahl S., et al. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology 230 2 (1997) 155-166
53. Prais D., Schonfeld T., and Amir J. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use. Pediatrics 112 3 Pt. 1 (2003) 548-552
54. Prince G.A., Jenson A.B., Horswood R.L., Camargo E., and Chanock R.M. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol 93 3 (1978) 771-791
55. Prince G.A., Horswood R.L., Berndt J., Suffin S.C., and Chanock R.M. Respiratory syncytial virus infection in inbred mice. Infect Immun 26 2 (1979) 764-766
56. Ramaswamy M., Shi L., Monick M.M., Hunninghake G.W., and Look D.C. Specific inhibition of type I interferon signal transduction by respiratory syncytial virus. Am J Respir Cell Mol Biol 30 6 (2004) 893-900
57. Ramaswamy M., Shi L., Varga S.M., Barik S., Behlke M.A., and Look D.C. Respiratory syncytial virus nonstructural protein 2 specifically inhibits type I interferon signal transduction. Virology 344 2 (2006) 328-339
58. Reeve C.A., Whitehall J.S., Buettner P.G., Norton R., Reeve D.M., and Francis F. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab. J Paediatr Child Health 42 5 (2006) 253-258
59. Schlender J., Schnorr J.J., Spielhoffer P., Cathomen T., Cattaneo R., Billeter M.A., et al. Interaction of measles virus glycoproteins with the surface of uninfected peripheral blood lymphocytes induces immunosuppression in vitro. Proc Natl Acad Sci USA 93 23 (1996) 13194-13199
60. Schlender J., Walliser G., Fricke J., and Conzelmann K.K. Respiratory syncytial virus fusion protein mediates inhibition of mitogen-induced T-cell proliferation by contact. J Virol 76 3 (2002) 1163-1170
61. Shaffer J.A., Bellini W.J., and Rota P.A. The C protein of measles virus inhibits the type I interferon response. Virology 315 2 (2003) 389-397
62. Sigurs N., Bjarnason R., Sigurbergsson F., and Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 161 5 (2000) 1501-1507
63. Spann K.M., Tran K.C., Chi B., Rabin R.L., and Collins P.L. Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected]. J Virol 78 8 (2004) 4363-4369
64. Stein R.T., Sherrill D., Morgan W.J., Holberg C.J., Halonen M., Taussig L.M., et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 354 9178 (1999) 541-545
65. Sullender W.M., Anderson K., and Wertz G.W. The respiratory syncytial virus subgroup B attachment glycoprotein: analysis of sequence, expression from a recombinant vector, and evaluation as an immunogen against homologous and heterologous subgroup virus challenge. Virology 178 1 (1990) 195-203
66. Taylor G., Stott E.J., Hughes M., and Collins A.P. Respiratory syncytial virus infection in mice. Infect Immun 43 2 (1984) 649-655
67. Techaarpornkul S., Collins P.L., and Peeples M.E. Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus. Virology 294 2 (2002) 296-304
68. Teng M.N., Whitehead S.S., Bermingham A., St Claire M., Elkins W.R., Murphy B.R., et al. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol 74 19 (2000) 9317-9321
69. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289 2 (2003) 179-186
70. Tripp R.A., Jones L.P., Haynes L.M., Zheng H., Murphy P.M., and Anderson L.J. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2 8 (2001) 732-738
71. Welliver T.P., Garofalo R.P., Hosakote Y., Hintz K.H., Avendano L., Sanchez K., et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 195 8 (2007) 1126-1136
72. Wertz G.W., Collins P.L., Huang Y., Gruber C., Levine S., and Ball L.A. Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein. Proc Natl Acad Sci USA 82 12 (1985) 4075-4079
73. Whitehead S.S., Juhasz K., Firestone C.Y., Collins P.L., and Murphy B.R. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol 72 5 (1998) 4467-4471
74. Wilkinson T.M., Donaldson G.C., Johnston S.L., Openshaw P.J., and Wedzicha J.A. Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173 8 (2006) 871-876
75. Wright P.F., Ikizler M.R., Gonzales R.A., Carroll K.N., Johnson J.E., and Werkhaven J.A. Growth of respiratory syncytial virus in primary epithelial cells from the human respiratory tract. J Virol 79 13 (2005) 8651-8654
76. Wright P.F., Karron R.A., Madhi S.A., Treanor J.J., King J.C., O'Shea A., et al. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis 193 4 (2006) 573-581
77. Zhang L., Peeples M.E., Boucher R.C., Collins P.L., and Pickles R.J. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 76 11 (2002) 5654-5666
78. Zimmer G., Budz L., and Herrler G. Proteolytic activation of respiratory syncytial virus fusion protein. Cleavage at two furin consensus sequences. J Biol Chem 276 (2001) 34